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Aims
To evaluate the efficacy and safety of the treatment of
psoriatic arthritis (PsA) patients with tumor necrosis
factor (TNF) antagonists in the Rheumatology Dept. of
Hospital de Santa Maria using the BioRePortAP.
Methods
The Portuguese Society of Rheumatology (SPR) devel-
oped an electronic medical chart coupled with a data-
base for the follow up of PsA patients, the BioRePortAP,
which was launched in May 2009. This evaluation was
based on all the PsA patients that were on active treat-
ment with TNF antagonists in September 2009 and
were registered in the BioRePortAP. All the previous
data on these patients were introduced in BioRePortAP
using the prospective paper based follow up protocol
that this Dept. was using since 1999. Only patients with
more than 9 months of treatment were analyzed.
Results
Forty-two patients with PsA, actively treated with anti-
TNF agents in September 2009, for at least 9 months,
were analyzed in BioRePortAP. Twenty-three patients
were male (55%) and nineteen were female (45%). The
average age of these patients was 49.8 ± 10.9 years old,
the average disease duration was of 10.7 ± 5.6 years
and the mean duration of biological therapy was of
37.8 ± 27.8 months. For the 81% of patients with per-
ipheral joint disease there was a mean reduction of
more than 80% in the swollen and tender joint counts,
and almost 50% in the HAQ value. In the 19% of the
patients with axial involvement the reduction of BAS-
DAI and BASFI was not statistically significant. On top
of that, PASI score suffered a reduction of 64%. Four-
teen patients (33.3%) had to switch their TNF antagonist
treatment. 58.8% of the switches were due to adverse
effects and 41.2% due to therapy failure. Regarding the
56 adverse reactions registered, only one was a severe
reaction. The remaining adverse reactions were not
severe and 67% of them were due to infections.
Discussion
The results of this first report of the use of the BioRe-
PortAP in clinical practice confirm the efficacy and
safety of TNF antagonist treatment in PsA. The results
shown here elucidate the potential applications of BioR-
ePortAP as a tool for efficacy and safety assessment of
PsA patients treated with biotechnological drugs.
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